Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Gallium Ga-68 Gozetotide

If you want to know more about the Gallium Ga-68 Gozetotide, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Gallium Ga-68 Gozetotide industry. More news about Gallium Ga-68 Gozetotide, are being released. Follow us / contact us for more Gallium Ga-68 Gozetotide information!
  • Drug Patent & Exclusivity Expiration Report - Week of March 17 2025

    2025-03-17

    This week, there are 9 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - SANTARUS INC's GLUMETZA, containing active ingredient METFORMIN HYDROCHLORIDE - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - INCYTE CORP's JAKAFI, containing active ingredient RUXOLITINIB PHOSPHATE - FRESENIUS KABI USA LLC's SMOFLIPID 20%, containing active ingredient FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - NOVEN PHARMACEUTICALS INC's XELSTRYM, containing active ingredient DEXTROAMPHETAMINE - NOBELPHARMA CO LTD's HYFTOR, containing active ingredient SIROLIMUS - NOVARTIS PHARMACEUTICALS CORP's LOCAMETZ, containing active ingredient GALLIUM GA-68 GOZETOTIDE Read More